期刊
TRANSLATIONAL ONCOLOGY
卷 14, 期 11, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2021.101197
关键词
-
类别
资金
- Damon Runyon Cancer Research Foundation [51-18]
- American Cancer Society Research Scholar award [RSG-20-060-01-RMC]
- National Cancer Institute [R01CA251753]
- National Cancer Institute, Bethesda, MD [CA016058]
Studies have shown that RNA editing as a molecular marker for predicting response to immunotherapy has high accuracy and confidence, and can clearly distinguish melanoma patients who are sensitive to immunotherapy.
Immunotherapy has improved the prognosis for many melanoma patients; however, our capacity to predict patient responses and to understand the biological differences between patients who will or will not respond is limited. Gene expression profiling of tumors from patients who respond to immunotherapy has focused on deriving primarily immune-related signatures; however, these have shown limited predictive power. Recent studies have highlighted the role of RNA editing in modulating resistance to immunotherapy. To evaluate the utility of RNA editing activity as a discriminative tool in predicting immunotherapy response, we conducted a retrospective analysis of RNA-sequencing data from melanoma patients treated with Pembrolizumab or Nivolumab. Here, we developed RNA editing signatures that can identify patients who will respond to immunotherapy with very high accuracy and confidence. Our analysis demonstrates that RNA editing is a strong discriminative tool for examining sensitivity of melanoma patients to immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据